The company launched two cGMP facilities in Irvine, California, supporting formulation development, clinical manufacturing, and commercial production of tablets and capsules.
The system is designed to support commercial production of amorphous solid dispersions used to improve the bioavailability of poorly soluble drug candidates.
The new facility at Flatiron Park in Boulder will support process development and analytical services adjacent to the company’s peptide API manufacturing site.
The partnership adds 10 GMP production lines and 350,000 liters of reactor capacity to support clinical- through commercial-scale active pharmaceutical ingredient supply.
The deal grants Earendil exclusive rights to WuXi’s payload-linker platform, combining AI-driven antibody discovery with integrated antibody-drug conjugate manufacturing.
The CDMO will present on process analytical technology, digital manufacturing, and real-time analytics as part of FDA’s CBER Advanced Manufacturing Seminar Series.
Ipsen invested in containment and transfer equipment at Quotient’s Pennsylvania facility to support ongoing commercial production of a highly potent therapy for an ultra-rare ...
The collaboration is designed to align GMP RNA production with cell processing to reduce technical handoffs, accelerate clinical timelines, and strengthen U.S. supply chain.
The 46,000-square-foot Denton, Texas facility, part of the company’s $23 billion investment to expand its U.S. operations, is expected to be operational in 2028.
The new 30,000-square-foot facility in Bengaluru is designed to help biopharma developers shorten timelines and improve process control across multiple biologic modalities.
Construction is set to begin in spring 2026, with the two facilities in North Chicago expected to be fully operational in 2029 and supported by 300 new hires.
The CRDMO’s hiring spree aims to meet rising global demand and support expanded active pharmaceutical ingredient capacity across its India and international sites.
The new facility, part of J&J’s previously announced $55 billion U.S. investment, will expand domestic capacity and support its pipeline of advanced treatments.
The deal pairs early-stage active pharmaceutical ingredient capabilities in Israel with Recipharm’s global late-stage and commercial manufacturing network.
The program will integrate AI-driven robotics into GMP cell therapy workflows to improve cycle times, durability, and scalability, according to the companies.